Literature DB >> 7644567

5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research.

G Griebel1.   

Abstract

An overview of the behavioral data arising from the vast literature concerning the involvement of 5-hydroxytryptamine (5-HT) neurotransmission in the regulation of anxiety is presented. More than 1300 experiments were carried out in this area and they provide evidence that: (1) results obtained in ethologically based animal models of anxiety with drugs stimulating 5-HT transmission are most consistent with the classic 5-HT hypothesis of anxiety in that they show an increase in animals' emotional reactivity; (2) no category of anti-anxiety models are selectively sensitive to the anxiolytic-like effects of drugs targetting 5-HT1A, 5-HT2A or 5-HT2C receptor subtypes; (3) anxiolytic-like effects of 5-HT3 receptor antagonists, in the great part, are revealed by models based on spontaneous behaviors. Taken together, these observations lead to the conclusion that different 5-HT mechanisms, mediated by different receptor subtypes, are involved in the genesis of anxiety.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7644567     DOI: 10.1016/0163-7258(95)98597-j

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  65 in total

1.  Serotonin receptors modulate GABA(A) receptor channels through activation of anchored protein kinase C in prefrontal cortical neurons.

Authors:  J Feng; X Cai; J Zhao; Z Yan
Journal:  J Neurosci       Date:  2001-09-01       Impact factor: 6.167

2.  Low doses of 8-OH-DPAT prevent the impairment of spatial learning caused by intrahippocampal scopolamine through 5-HT(1A) receptors in the dorsal raphe.

Authors:  M Carli; C Balducci; R Samanin
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

3.  Effects of sustained (+/-)pindolol administration on serotonin neurotransmission in rats.

Authors:  N Haddjeri; P Blier
Journal:  J Psychiatry Neurosci       Date:  2000-09       Impact factor: 6.186

4.  On the anxiogenic and anxiolytic nature of long-term cerebral 5-HT depletion following MDMA.

Authors:  A Richard Green; Iain S McGregor
Journal:  Psychopharmacology (Berl)       Date:  2002-08       Impact factor: 4.530

5.  Effects of clathrate formation on the activity of pharmacons in their complexes with glycyrrhizic acid.

Authors:  T G Tolstikova; I V Sorokina; I L Kovalenko; A G Tolstikov
Journal:  Dokl Biol Sci       Date:  2004 Jan-Feb

6.  The HTR3A polymorphism c. -42C>T is associated with amygdala responsiveness in patients with irritable bowel syndrome.

Authors:  Lisa A Kilpatrick; Jennifer S Labus; Kristen Coveleskie; Christian Hammer; Gudrun Rappold; Kirsten Tillisch; Joshua A Bueller; Brandall Suyenobu; Johana M Jarcho; Jim A McRoberts; Beate Niesler; Emeran A Mayer
Journal:  Gastroenterology       Date:  2011-03-21       Impact factor: 22.682

7.  Effects of milnacipran in animal models of anxiety and memory.

Authors:  Vânia K M Moojen; Márcio Rodrigo Martins; Adalisa Reinke; Gustavo Feier; Fabiano R Agostinho; Edson M Cechin; João Quevedo
Journal:  Neurochem Res       Date:  2006-05-09       Impact factor: 3.996

Review 8.  The serotonin1A receptor: a representative member of the serotonin receptor family.

Authors:  Thomas J Pucadyil; Shanti Kalipatnapu; Amitabha Chattopadhyay
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

Review 9.  Serotonin 1A and Serotonin 4 Receptors: Essential Mediators of the Neurogenic and Behavioral Actions of Antidepressants.

Authors:  Benjamin Adam Samuels; Indira Mendez-David; Charlène Faye; Sylvain André David; Kerri A Pierz; Alain M Gardier; René Hen; Denis J David
Journal:  Neuroscientist       Date:  2014-12-08       Impact factor: 7.519

10.  Modulation of neuronal excitability by serotonin-NMDA interactions in prefrontal cortex.

Authors:  Ping Zhong; Eunice Y Yuen; Zhen Yan
Journal:  Mol Cell Neurosci       Date:  2008-03-25       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.